190 related articles for article (PubMed ID: 36152216)
1. Tralokinumab Efficacy and Safety, with or without Topical Corticosteroids, in North American Adults with Moderate-to-Severe Atopic Dermatitis: A Subanalysis of Phase 3 Trials ECZTRA 1, 2, and 3.
Blauvelt A; Gooderham M; Bhatia N; Langley RG; Schneider S; Zoidis J; Kurbasic A; Armstrong A; Silverberg JI
Dermatol Ther (Heidelb); 2022 Nov; 12(11):2499-2516. PubMed ID: 36152216
[TBL] [Abstract][Full Text] [Related]
2. Tralokinumab Plus Topical Corticosteroids as Needed Provides Progressive and Sustained Efficacy in Adults with Moderate-to-Severe Atopic Dermatitis Over a 32-Week Period: An ECZTRA 3 Post Hoc Analysis.
Silverberg JI; Adam DN; Zirwas M; Kalia S; Gutermuth J; Pinter A; Pink AE; Chiricozzi A; Barbarot S; Mark T; Tindberg AM; Weidinger S
Am J Clin Dermatol; 2022 Jul; 23(4):547-559. PubMed ID: 35857179
[TBL] [Abstract][Full Text] [Related]
3. Tralokinumab Efficacy Over 1 Year in Adults with Moderate-to-Severe Atopic Dermatitis: Pooled Data from Two Phase III Trials.
Simpson EL; Pink AE; Blauvelt A; Gooderham M; Armstrong AW; Worm M; Katoh N; Peris K; Puig L; Barbarot S; Mark T; Steffensen LA; Tindberg AM; Wollenberg A
Am J Clin Dermatol; 2023 Nov; 24(6):939-952. PubMed ID: 37682422
[TBL] [Abstract][Full Text] [Related]
4. Tralokinumab for moderate-to-severe atopic dermatitis: results from two 52-week, randomized, double-blind, multicentre, placebo-controlled phase III trials (ECZTRA 1 and ECZTRA 2).
Wollenberg A; Blauvelt A; Guttman-Yassky E; Worm M; Lynde C; Lacour JP; Spelman L; Katoh N; Saeki H; Poulin Y; Lesiak A; Kircik L; Cho SH; Herranz P; Cork MJ; Peris K; Steffensen LA; Bang B; Kuznetsova A; Jensen TN; Østerdal ML; Simpson EL;
Br J Dermatol; 2021 Mar; 184(3):437-449. PubMed ID: 33000465
[TBL] [Abstract][Full Text] [Related]
5. Tralokinumab Provides Clinically Meaningful Responses at Week 16 in Adults with Moderate-to-Severe Atopic Dermatitis Who Do Not Achieve IGA 0/1.
Simpson EL; Blauvelt A; Silverberg JI; Cork MJ; Katoh N; Mark T; Schneider SKR; Wollenberg A
Am J Clin Dermatol; 2024 Jan; 25(1):139-148. PubMed ID: 37804473
[TBL] [Abstract][Full Text] [Related]
6. Efficacy and Safety of Tralokinumab in Adolescents With Moderate to Severe Atopic Dermatitis: The Phase 3 ECZTRA 6 Randomized Clinical Trial.
Paller AS; Flohr C; Cork M; Bewley A; Blauvelt A; Hong HC; Imafuku S; Schuttelaar MLA; Simpson EL; Soong W; Arlert P; Lophaven KW; Kurbasic A; Soldbro L; Vest NS; Wollenberg A
JAMA Dermatol; 2023 Jun; 159(6):596-605. PubMed ID: 37074705
[TBL] [Abstract][Full Text] [Related]
7. Tralokinumab plus topical corticosteroids for the treatment of moderate-to-severe atopic dermatitis: results from the double-blind, randomized, multicentre, placebo-controlled phase III ECZTRA 3 trial.
Silverberg JI; Toth D; Bieber T; Alexis AF; Elewski BE; Pink AE; Hijnen D; Jensen TN; Bang B; Olsen CK; Kurbasic A; Weidinger S;
Br J Dermatol; 2021 Mar; 184(3):450-463. PubMed ID: 33000503
[TBL] [Abstract][Full Text] [Related]
8. Matching-Adjusted Indirect Comparison of the Efficacy at Week 32 of Tralokinumab and Dupilumab in the Treatment of Moderate-to-Severe Atopic Dermatitis.
Torres T; Sohrt Petersen A; Ivens U; Bosch Vilaro A; Stinson J; Carrascosa JM
Dermatol Ther (Heidelb); 2024 Apr; 14(4):983-992. PubMed ID: 38613642
[TBL] [Abstract][Full Text] [Related]
9. Tralokinumab plus topical corticosteroids in adults with severe atopic dermatitis and inadequate response to or intolerance of ciclosporin A: a placebo-controlled, randomized, phase III clinical trial (ECZTRA 7).
Gutermuth J; Pink AE; Worm M; Soldbro L; Bjerregård Øland C; Weidinger S
Br J Dermatol; 2022 Mar; 186(3):440-452. PubMed ID: 34698371
[TBL] [Abstract][Full Text] [Related]
10. Patient-oriented measures for phase 3 studies of tralokinumab for the treatment of atopic dermatitis (ECZTRA 1, 2, and 3).
Simpson EL; Wollenberg A; Soong W; Steffensen LA; Kurbasic A; Schneider S; Zoidis J; Silverberg JI
Ann Allergy Asthma Immunol; 2022 Nov; 129(5):592-604.e5. PubMed ID: 35843520
[TBL] [Abstract][Full Text] [Related]
11. Safety and Efficacy of Tralokinumab in Older Adults With Moderate-to-Severe Atopic Dermatitis: A Secondary Analysis.
Merola JF; Butler DC; Mark T; Schneider S; Kim Y; Abuabara K
JAMA Dermatol; 2023 Oct; 159(10):1119-1123. PubMed ID: 37610789
[TBL] [Abstract][Full Text] [Related]
12. Safety and efficacy of upadacitinib in combination with topical corticosteroids in adolescents and adults with moderate-to-severe atopic dermatitis (AD Up): results from a randomised, double-blind, placebo-controlled, phase 3 trial.
Reich K; Teixeira HD; de Bruin-Weller M; Bieber T; Soong W; Kabashima K; Werfel T; Zeng J; Huang X; Hu X; Hendrickson BA; Ladizinski B; Chu AD; Silverberg JI
Lancet; 2021 Jun; 397(10290):2169-2181. PubMed ID: 34023009
[TBL] [Abstract][Full Text] [Related]
13. Long-term management of moderate-to-severe atopic dermatitis with dupilumab and concomitant topical corticosteroids (LIBERTY AD CHRONOS): a 1-year, randomised, double-blinded, placebo-controlled, phase 3 trial.
Blauvelt A; de Bruin-Weller M; Gooderham M; Cather JC; Weisman J; Pariser D; Simpson EL; Papp KA; Hong HC; Rubel D; Foley P; Prens E; Griffiths CEM; Etoh T; Pinto PH; Pujol RM; Szepietowski JC; Ettler K; Kemény L; Zhu X; Akinlade B; Hultsch T; Mastey V; Gadkari A; Eckert L; Amin N; Graham NMH; Pirozzi G; Stahl N; Yancopoulos GD; Shumel B
Lancet; 2017 Jun; 389(10086):2287-2303. PubMed ID: 28478972
[TBL] [Abstract][Full Text] [Related]
14. Review of Tralokinumab in the Treatment of Atopic Dermatitis.
Singh R; Taylor A; Shah MA; Strowd LC; Feldman SR
Ann Pharmacother; 2023 Mar; 57(3):333-340. PubMed ID: 35730479
[TBL] [Abstract][Full Text] [Related]
15. Safety of tralokinumab in adult patients with moderate-to-severe atopic dermatitis: pooled analysis of five randomized, double-blind, placebo-controlled phase II and phase III trials.
Simpson EL; Merola JF; Silverberg JI; Reich K; Warren RB; Staumont-Sallé D; Girolomoni G; Papp K; de Bruin-Weller M; Thyssen JP; Zachariae R; Olsen CK; Wollenberg A
Br J Dermatol; 2022 Dec; 187(6):888-899. PubMed ID: 36082590
[TBL] [Abstract][Full Text] [Related]
16. Once-daily upadacitinib versus placebo in adolescents and adults with moderate-to-severe atopic dermatitis (Measure Up 1 and Measure Up 2): results from two replicate double-blind, randomised controlled phase 3 trials.
Guttman-Yassky E; Teixeira HD; Simpson EL; Papp KA; Pangan AL; Blauvelt A; Thaçi D; Chu CY; Hong HC; Katoh N; Paller AS; Calimlim B; Gu Y; Hu X; Liu M; Yang Y; Liu J; Tenorio AR; Chu AD; Irvine AD
Lancet; 2021 Jun; 397(10290):2151-2168. PubMed ID: 34023008
[TBL] [Abstract][Full Text] [Related]
17. Long-Term Efficacy and Safety of Dupilumab in Adolescents with Moderate-to-Severe Atopic Dermatitis: Results Through Week 52 from a Phase III Open-Label Extension Trial (LIBERTY AD PED-OLE).
Blauvelt A; Guttman-Yassky E; Paller AS; Simpson EL; Cork MJ; Weisman J; Browning J; Soong W; Sun X; Chen Z; Kosloski MP; Kamal MA; Delevry D; Chuang CC; O'Malley JT; Bansal A
Am J Clin Dermatol; 2022 May; 23(3):365-383. PubMed ID: 35567671
[TBL] [Abstract][Full Text] [Related]
18. Tralokinumab in Atopic Dermatitis: A Profile of Its Use.
Blair HA
Clin Drug Investig; 2022 Apr; 42(4):365-374. PubMed ID: 35316850
[TBL] [Abstract][Full Text] [Related]
19. Efficacy and Safety of Lebrikizumab in Combination With Topical Corticosteroids in Adolescents and Adults With Moderate-to-Severe Atopic Dermatitis: A Randomized Clinical Trial (ADhere).
Simpson EL; Gooderham M; Wollenberg A; Weidinger S; Armstrong A; Soung J; Ferrucci S; Lima RG; Witte MM; Xu W; ElMaraghy H; Natalie CR; Pierce E; Blauvelt A;
JAMA Dermatol; 2023 Feb; 159(2):182-191. PubMed ID: 36630140
[TBL] [Abstract][Full Text] [Related]
20. Short-term efficacy and safety of biologics and Janus kinase inhibitors for patients with atopic dermatitis: A systematic review and meta-analysis.
Chen Q; Cui L; Hu Y; Chen Z; Gao Y; Shi Y
Heliyon; 2023 Nov; 9(11):e22014. PubMed ID: 38034798
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
